Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Provide Business Update and Report Second Quarter 2023 Financial Results on August 3, 2023

Key Takeaway: Vir Biotechnology, Inc. has announced that it will provide a corporate update and report its financial results for the second quarter of 2023 on August 3, 2023. The update will be shared through a press release after market close and will be followed by a conference call at 4:30 p.m. Eastern Time. The company focuses on enhancing the immune system to treat serious infectious diseases, with ongoing development efforts targeting diseases such as hepatitis B, influenza A, and COVID-19.
Price reaction · baseline $13.99 (2023-07-25 close) · hit after-hours · clean, no other VIR news in the window
day 0 close · peak
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Vir Biotechnology is actively updating its stakeholders, showing transparency.
  • The company continues to engage with investors through conference calls.
  • Product pipeline includes treatments for critical infectious diseases.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+32%
120-day peak, hindsight
Typical move
14%
average across 4 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO, July 26, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may access the conference call via webcast on the Events & Presentations page of Vir’s website at https://investors.vir.bio/events-presentations. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled three technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B and D viruses, influenza A, human immunodeficiency virus and COVID-19. Vir routinely posts information that may be important to investors on its website.

Frequently Asked Questions

When will Vir Biotechnology announce its Q2 2023 results?

Vir Biotechnology will announce its Q2 2023 results on August 3, 2023.

What time is the Vir conference call scheduled?

The conference call is scheduled for 4:30 p.m. Eastern Time on August 3, 2023.

Where can I access the financial results press release?

The press release will be available in the Investors section of Vir's website.

How long will the recorded conference call be available?

The recorded conference call will be available for 30 days on their website.

What is the focus of Vir Biotechnology?

Vir Biotechnology focuses on treating serious infectious diseases using immunologic insights.

Last updated: Jul 26, 2023